We are live on ! Find out more
CODX

Co-Diagnostics

77 hedge funds and large institutions have $63.7M invested in Co-Diagnostics in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 32 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.1% less ownership

Funds ownership: 0.92%0.82% (-0.1%)

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1% less funds holding

Funds holding: 7877 (-1)

18% less capital invested

Capital invested by funds: $77.6M → $63.7M (-$13.9M)

22% less call options, than puts

Call options by funds: $5.6M | Put options by funds: $7.19M

44% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 32

Holders
77
Holders Change
-1
Holders Change %
-1.28%
% of All Funds
1.18%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
18
Reduced
32
Closed
17
Calls
$5.6M
Puts
$7.19M
Net Calls
-$1.58M
Net Calls Change
+$466K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$16M -$23.9K -91 -0.2%
Millennium Management
2
Millennium Management
New York
$4.98M -$1.72M -6,575 -26%
PPA
3
Parametric Portfolio Associates
Washington
$4.9M +$196K +748 +4%
BlackRock
4
BlackRock
New York
$4.38M -$357K -1,361 -8%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$3.42M -$353K -1,347 -10%
ARC
6
Advisor Resource Council
Texas
$2.65M
Renaissance Technologies
7
Renaissance Technologies
New York
$2.63M +$962K +3,667 +60%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.29M -$1.31K -5 -0.1%
Russell Investments Group
9
Russell Investments Group
United Kingdom
$2.16M -$796K -3,033 -27%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$1.66M +$137K +521 +9%
EIP
11
Easterly Investment Partners
Massachusetts
$1.4M -$43.5K -166 -3%
CSS
12
Cubist Systematic Strategies
Connecticut
$1.09M +$401K +1,527 +60%
SIM
13
SummerHaven Investment Management
Connecticut
$978K
Goldman Sachs
14
Goldman Sachs
New York
$763K +$303K +1,156 +68%
State Street
15
State Street
Massachusetts
$746K -$79.5K -303 -10%
AC
16
Aristides Capital
Kentucky
$685K +$671K +2,557 New
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$680K -$312K -1,189 -32%
Citadel Advisors
18
Citadel Advisors
Florida
$669K -$401K -1,530 -38%
Principal Financial Group
19
Principal Financial Group
Iowa
$668K -$572K -2,180 -47%
Morgan Stanley
20
Morgan Stanley
New York
$596K -$618K -2,355 -51%
EGM
21
Engineers Gate Manager
New York
$576K +$40.7K +155 +8%
American Century Companies
22
American Century Companies
Missouri
$571K +$559K +2,130 New
PC
23
Prairiewood Capital
North Dakota
$532K +$1.84K +7 +0.4%
AFM
24
Anson Funds Management
Texas
$488K +$477K +1,820 New
Group One Trading
25
Group One Trading
Illinois
$483K -$88.7K -338 -16%

CODX Hedge Fund Activity: Q4 2021 in Review

77 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2021, worth a combined $63.7M — down 18% from $77.6M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CODX and 16 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 18 added.

The largest buyer was Renaissance Technologies, adding an estimated $962K. The largest seller was Marshall Wace, exiting entirely with an estimated $2.15M sold.

  • 77 institutional investors held Co-Diagnostics (CODX) as of Q4 2021, down from 78 in Q3 2021.
  • Funds reported $63.7M of Co-Diagnostics stock for Q4 2021, down 18% quarter-over-quarter.
  • 16 funds opened new Co-Diagnostics positions in Q4 2021 and 17 closed out, a net change of -1 holder.
  • The largest Co-Diagnostics buyer in Q4 2021 was Renaissance Technologies, an estimated $962K added.
  • The largest Co-Diagnostics seller in Q4 2021 was Marshall Wace, an estimated $2.15M sold.

Based on aggregated 13F filings for Q4 2021.